Hippo Signaling in the Lung: A Tale of Two Effectors—Yap Drives Airway Fate and Taz Drives Alveolar Differentiation
Cells · 2026
DOI: 10.3390/cells15020143 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Rachel Warren und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary and Critical Medicine, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Cell Differentiation, Lung, Hippo Signaling Pathway, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Mayo Clinic Brewer Family Career Development Award (RW)., National Heart Lung and Blood Institute.
Abstract (Originalsprache)
The mammalian lung operates under a biological paradox, requiring architectural fragility for gas exchange while maintaining robust regenerative plasticity to withstand injury. The Hippo signaling pathway has emerged as a central “rheostat” in orchestrating these opposing needs, yet the distinct roles of its downstream effectors remain underappreciated. This review synthesizes recent genetic and mechanobiological advances to propose a “Tale of Two Effectors” model, arguing for the functional non-redundancy of YAP and TAZ. We posit that YAP functions to drive airway progenitor expansion, mechanical force generation, and maladaptive remodeling. Conversely, TAZ—regulated uniquely via transcriptional mechanisms and mechanotransduction—acts as an obligate driver of alveolar differentiation and adaptive repair through an NKX2-1 feed-forward loop. Furthermore, we introduce the “See-Saw” model of tissue fitness, where mesenchymal niche collapse releases the mechanical brake on the epithelium, triggering the bronchiolization characteristic of pulmonary fibrosis. Finally, we extend this framework to malignancy, illustrating how Small Cell Lung Cancer (SCLC) subtypes mirror these developmental and regenerative states. This integrated framework offers new therapeutic distinct targets for modulating tissue fitness and resolving fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Pulmonary and Critical Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Stijn P J De Langhe
Förderung
- NHLBI NIH HHS
- Mayo Clinic Brewer Family Career Development Award (RW).
- National Heart Lung and Blood Institute
Zitieren
APA
Warren, R., & De Langhe, S. P. J. (2026). Hippo Signaling in the Lung: A Tale of Two Effectors—Yap Drives Airway Fate and Taz Drives Alveolar Differentiation. Cells. https://doi.org/10.3390/cells15020143
Vancouver
Warren R, De Langhe SPJ. Hippo Signaling in the Lung: A Tale of Two Effectors—Yap Drives Airway Fate and Taz Drives Alveolar Differentiation. Cells. 2026. doi:10.3390/cells15020143
BibTeX
@article{Warren2026,
author = {Warren, Rachel and De Langhe, Stijn P J},
title = {Hippo Signaling in the Lung: A Tale of Two Effectors—Yap Drives Airway Fate and Taz Drives Alveolar Differentiation},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15020143}
}
EUVIMED